A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers

Overview

This randomized, double-blind, parallel-arm study will assess the safety and tolerability of RO4995819 in combination with citalopram in healthy volunteers. Subjects will receive citalopram orally on Days 1-9 and be randomized to receive either RO4995819 orally or placebo in combination with citalopram on Days 10-16. Safety follow-up will be up to Day 58.

Full Title of Study: “A Single Center, Randomized, Double-blind, Parallel-design Study to Investigate the Safety and Tolerability of RO4995819 in Combination With Citalopram Following Oral Administration in Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 2011

Interventions

  • Drug: RO4995819
    • multiple oral doses, Days 10-16
  • Drug: citalopram
    • multiple oral doses, Days 1-16
  • Drug: placebo
    • multiple oral doses, Days 10-16

Arms, Groups and Cohorts

  • Experimental: 1
  • Placebo Comparator: 2

Clinical Trial Outcome Measures

Primary Measures

  • Safety: Incidence of adverse events
    • Time Frame: up to 58 days

Secondary Measures

  • Effect of multiple doses of RO4995819 on the pharmacokinetics (Cmax, AUC) of citalopram
    • Time Frame: 17 days
  • Effect of genetic variants of drug metabolism on pharmacokinetics (Cmax, AUC) of RO4995819 in combination with citalopram
    • Time Frame: up to 58 days

Participating in This Clinical Trial

Inclusion Criteria

  • Adult healthy male or female subjects, 18 to 65 years of age inclusive (healthy status defined as absence of evidence of any active or chronic disease) – Body mass index (BMI) 18.0 to 30.0 kg/m2 inclusive – Female subjects who are not either surgically sterile or post-menopausal must commit to using a barrier form of contraception in addition to either an intrauterine device or hormonal contraception until at least 5 months after the last dose of study drug – Male subjects must use a barrier method of contraception throughout the study and for up to 5 months after the last dose of study drug (applies also to surgically sterilized males) – Willing not to participate in any other clinical trial with an investigational drug for at least 5 months following the last dose of study drug Exclusion Criteria:

  • Pregnant or lactating females – Suspicion of regular consumption of drug of abuse or positive test for alcohol on Day -2 – Hepatitis B, hepatitis C or HIV infection – Smokers of >5 cigarettes or equivalent tobacco intake per day – Any confirmed allergic reaction against any drug, or multiple allergies (non-active hay fever is acceptable) – Participation in an investigational drug or device study within 3 months prior to dosing

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Hoffmann-La Roche
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clinical Trials, Study Director, Hoffmann-La Roche

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.